AMGEN INC (AMGN)

US0311621009 - Common Stock

263.38  +2.19 (+0.84%)

After market: 263.38 0 (0%)

AMGEN INC

NASDAQ:AMGN (12/20/2024, 8:00:00 PM)

After market: 263.38 0 (0%)

263.38

+2.19 (+0.84%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%12.5%
Sales Q2Q%23.18%
CRS19.77
6 Month-14.53%
Overview
Earnings (Last)10-30 2024-10-30/amc
Earnings (Next)02-04 2025-02-04/amc
Ins Owners0.07%
Inst Owners80.93%
Market Cap141.57B
Shares537.53M
PE13.7
Fwd PE12.52
Dividend Yield3.64%
Analysts73.85
Short Float %2.08%
Short Ratio3.48
IPO06-17 1983-06-17
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AMGN Daily chart

Company Profile

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company is headquartered in Thousand Oaks, California and currently employs 26,700 full-time employees. The firm discovers, develops, manufactures and delivers various human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and improve people's lives. The company operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine), KYPROLIS (carfilzomib), Maridebart cafraglutide, (infliximab-axxq), Evenity, LumaKras, Nplate and XGeva, others.

Company Info

AMGEN INC

One Amgen Center Drive

Thousand Oaks CALIFORNIA 91320

P: 18054471000

CEO: Robert A. Bradway

Employees: 26700

Website: https://www.amgen.com/

AMGN News

News Image2 days ago - Market News VideoDow Movers: MSFT, AMGN
News Image3 days ago - Investor's Business DailyIs Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

News Image3 days ago - Investor's Business DailyNovo Nordisk Dives On CagriSegma Obesity Drug Trial. Eli Lilly, Viking Jump.

Eli Lilly and Viking Therapeutics jumped on Novo's setback.

News Image3 days ago - Investor's Business Daily10 Biggest Losers of The Dow Jones Index's 10-Day Losing Streak

Investors shrugged off the meltdown on Thursday. A few Dow laggards rebounded.

News Image7 days ago - Investor's Business DailyViridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease

The company's drug led to an improvement in diplopia, or double vision, an area where Amgen's Tepezza hasn't worked.

News Image7 days ago - Investor's Business DailyBattle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?

The weight-loss drugs space continues to heat up. Here's the latest news from the segment.

AMGN Twits

Here you can normally see the latest stock twits on AMGN, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example